BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|February 25, 2021
Pharmacy Practice in Focus: Oncology
- February 2021
- Volume 3
- Issue 1
CE: Innovations in Acute Graft-Versus-Host Disease: Pharmacy Updates on Risk Assessment, Prevention, and Treatment
This activity is supported by an educational grant from Incyte Corporation.
Advertisement
This activity is supported by an educational grant from Incyte Corporation.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Apply risk scoring tools for assessing grade and stage of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) recipients
- Examine emerging strategies in the prevention and treatment of aGVHD
- Maximize the role of the pharmacist of the HSCT team to improve patient outcomes
FACULTY
Nicole Watts, PharmD, BCOP
Clinical Pharmacy Specialist, Blood and Bone Marrow Transplant , University of Alabama at Birmingham Hospital , Birmingham, Alabama
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: November 30, 2020
EXPIRATION DATE: August 30, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours
FEE: This lesson is offered for free at
Articles in this issue
over 5 years ago
Oncology Care Pharmacy Has Promising Trends on the Horizonover 5 years ago
Utilizing Pharmacogenomics Information to Guide AML TreatmentAdvertisement
Related to this article
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5